当前位置:
编号:1971516
阿帕替尼单药用于多线治疗失败后的晚期卵巢癌1例
http://www.100md.com 2020年4月11日 《中国实用医药》 2020年第2期
     附录影像学资料。

    参考文献

    [1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 2015, 65(2):87-108.

    [2] Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006, 33(2 Suppl 6):S3-11.

    [3] Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Design Development & Therapy, 2015(9):6075-6081.

    [4] Lin Y, Zhai E, Liao B, et al. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer. 2017, 8(7):11990-12002.

    [5] Bi J, Liu H, Huang Y. The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature. International Medical Case Reports Journal, Volume, 2017(10):223-227.

    [6] 李琪, 史曉宇, 赵丽霞, 等. 阿帕替尼联合化疗用于二线治疗失败晚期卵巢癌的临床观察. 河北医科大学学报, 2017, 38(12):

    1384-1387.

    [7] 王丽丽, 李鑫, 侯定坤, 等. 阿帕替尼治疗6例晚期难治性卵巢癌的临床观察. 中国肿瘤临床, 2018, 45(7):362-365.

    [8] 孙璐, 刘翔宇, 于虎, 等. 甲磺酸阿帕替尼治疗二线化疗失败上皮性卵巢癌的疗效分析. 中国肿瘤临床, 2019, 46(12):627-630.

    [收稿日期:2019-11-19], http://www.100md.com(杨雪芹 冀学宁)